Warfarin sodium

Base Information

• Chemical Name: Warfarin sodium
• CAS No.: 129-06-6
• Molecular Formula: C19H16NaO4
• Molecular Weight: 332.331
• Hs Code.: 29322090
• Mol file: 129-06-6.mol

Synonyms:3-(a-Acetonylbenzyl)-4-hydroxycoumarinsodium;Aldocumar;Athrombin;Coumadin;Coumadine;Dimantil;Marevam;Orfarin;Panwarfin;Prothromadin;Simarc 2;Sodiumwarfarin;Sofarin;Tintorane;Varfine;Waran;Warfarina;Warfil 5;Zoocoumarin sodium salt;2H-1-Benzopyran-2-one,4-hydroxy-3-(3-oxo-1-phenylbutyl)-, sodium salt (9CI);Coumarin, 3-(a-acetonylbenzyl)-4-hydroxy-, sodium salt (8CI);

Chemical Property of Warfarin sodium

Chemical Property:

• Appearance/Colour: white or yellowish powder
• Melting Point: approximate 161℃
• Boiling Point: 515.2oC at 760mmHg
• Flash Point: 188.8oC
• PSA: 70.34000
• Density: 1.307g/cm3
• LogP: 4.04780
• Storage Temp.: 2-8°C
• Solubility.: Very soluble in water and in ethanol (96 per cent), soluble in acetone, very slightly soluble in methylene chloride.

Purity/Quality:

99% ^*data from raw suppliers

(±)-WarfarinSodium ^*data from reagent suppliers

Safty Information:

• Pictogram(s): T+
• Hazard Codes: T+
• Statements: 61-28
• Safety Statements: 53-36/37/39-45-36/37-28

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Uses: Warfarin Sodium (Crystalline Clathrate) is used for pharmaceutical care for patients with chronic heart failure and renal dysfunction. central stimulant Rodenticide.
• Therapeutic Function: Anticoagulant
• Clinical Use: By virtue of its great potency, warfarin sodium at firstwas considered unsafe for use in humans and was used veryeffectively as a rodenticide, especially against rats. At theproper dosage level, however, it can be used in humans, especiallythrough the intravenous route.
• Drug interactions: Potentially hazardous interactions with other drugs There are many significant interactions with warfarin. Prescribe with care with regard to the following: Anticoagulant effect enhanced by: alcohol, amiodarone, anabolic steroids, aspirin, aztreonam, bicalutamide, cephalosporins, chloramphenicol, cimetidine, ciprofloxacin, clopidogrel, cranberry juice, danazol, danshen, dipyridamole, dronedarone, disulfiram, entacapone, esomeprazole, exenatide, ezetimibe, fibrates, fluconazole, flutamide, fluvastatin, glucosamine, grapefruit juice, itraconazole, ketoconazole, levamisole, levofloxacin, macrolides, methylphenidate, metronidazole, miconazole, mirtazepine, nalidixic acid, neomycin, norfloxacin, NSAIDs, ofloxacin, omeprazole, pantoprazole, paracetamol, penicillins, proguanil, propafenone, ritonavir, rosuvastatin, saquinavir, SSRIs, simvastatin, sulfinpyrazone, sulphonamides, tamoxifen, tegafur, testosterone, tetracyclines, thyroid hormones, tigecycline, toremifene, tramadol, trimethoprim, valproate, venlafaxine, vitamin E and voriconazole. Anticoagulant effect decreased by: acitretin, atorvastatin, azathioprine, barbiturates, carbamazepine, enteral feeds, eslicarbazepine, enzalutamide, fosphenytoin, ginseng, griseofulvin, oral contraceptives, phenobarbital, phenytoin, primidone, rifamycins, St John’s wort (avoid concomitant use), sucralfate, vitamin K. Anticoagulant effects enhanced / reduced by: anion exchange resins, atazanavir, corticosteroids, dietary changes, disopyramide, efavirenz, fosamprenavir, nevirapine, ritonavir, telaprevir, tricyclics, trazodone. Analgesics: increased risk of bleeding with IV diclofenac and ketorolac - avoid concomitant use. Anticoagulants: increased risk of haemorrhage with apixaban, dabigatran, edoxaban and rivaroxaban - avoid concomitant use. Antidiabetic agents: enhanced hypoglycaemic effect with sulphonylureas; also possible changes to anticoagulant effect. Camomile: enhanced anticoagulation. Ciclosporin: there have been a few reports of altered anticoagulant effect; decreased ciclosporin levels have been seen rarely. Cytotoxics: increased risk of bleeding with erlotinib, imatinib and regorafenib; enhanced effect with capecitabine, etoposide, fluorouracil, ifosfamide, gefitinib, gemcitabine, sorafenib and vemurafenib; reduced effect with mercaptopurine and mitotane. Melatonin: possibly enhanced INR.

Technology Process of Warfarin sodium

There total 2 articles about Warfarin sodium which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

warfarin (81-81-2) → warfarin (129-06-6)

Guidance literature:

With sodium hydroxide; In water; at 25 - 55 ℃; for 2h; Product distribution / selectivity;

Reference yield:

→ warfarin sodium (129-06-6,12795-55-0,51821-81-9,5543-79-3)

Guidance literature:

Reference yield: 95.0%

lanthanum(III) chloride (10099-58-8) + warfarin (129-06-6) → La(3+)*3C19H15O4(1-)*6H2O=La(C19H15O4)3*6H2O

Guidance literature:

In water; dropwise addn. of soln. of Ln-salt to soln. of ligand salt (pptn.), stirring (0.5 h); filtration, washing (H2O), drying (vac. desiccator); elem. anal.;

DOI:10.1080/00945719909349483

upstream raw materials:

warfarin

Downstream raw materials:

4'-Hydroxywarfarin

Refernces

• 1、 -. "PROCESS FOR SYNTHESIS OF PURE WARFARIN ACID, WARFARIN ALKALI METAL SALTS AND CORRESPONDING CLATHRATES". . . Retrieved 2008/06/13.